90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions
Acurx Pharmaceuticals shares have fallen about 90% from their 52-week high, trading near $4.30 after a 1-for-20 reverse split in August. The stock briefly rallied in late September after the European Medicines Agency issued a positive opinion on its pediatric plan for ibezapolstat. Acurx remains pre-revenue with $6.1 million in cash at Q2’s end and faces additional funding needs for Phase 3 trials.
